Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group
Background Sorafenib is an oral small molecule inhibitor of multiple kinases controlling tumor growth and angiogenesis. The purpose of the phase 2 study was to determine the response rate of sorafenib and gain further information on the associated toxicities, pharmacokinetics, and pharmacodynamics o...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | 英語 |
| 出版事項: |
2015
|
| オンライン･アクセス: | https://doi.org/10.1002/pbc.25548 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|